Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]

Maftivimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetZaire ebolavirus glycoprotein
Clinical data
Pronunciationmaf tiv' i mab
License data
Drug classMonoclonal antibody
ATC code
  • None
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6368H9886N1706O2008S46
Molar mass143947.83 g·mol−1

References

edit
  1. ^ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020.   This article incorporates text from this source, which is in the public domain.
  2. ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
edit